title: Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective.
abstract: The incidence rate of breast cancers in People's Republic of China has increased in the last decade, and many cases are responsive to hormone therapies. The third-generation aromatase inhibitor letrozole inhibits estrogen production, and is more efficacious than the estrogen receptor inhibitor tamoxifen. In recent years, letrozole has been widely used to treat postmenopausal breast cancers in People's Republic of China. Also, metastatic, premenopausal, and male breast cancers have been effectively treated by a combination of letrozole with cytotoxic, radiation, or other therapies. In this review, we provide a perspective and summary of recent advances in the use of letrozole for breast cancer in Chinese patients.
authors.affiliation: National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, Wuxi, People's Republic of China.
authors.forename: Dong-Xu
authors.initials: DX
authors.lastname: He
authors.affiliation: School of Pharmaceutical Sciences, Jiangnan University, Wuxi, People's Republic of China.
authors.forename: Xin
authors.initials: X
authors.lastname: Ma
keywords: Chinese; breast cancer; letrozole